早孕期剖宫产瘢痕妊娠:国际登记处治疗方案的比较分析
该国际登记处纳入2018年8月29日至2023年2月28日19国31中心460例早孕期剖宫产瘢痕妊娠(281例活胎、179例失败妊娠),比较手术、药物、球囊等治疗的有效性与安全性。吸引刮宫成功率91.5%,全身甲氨蝶呤仅59.4%,手术治疗成功率91.5%、并发症9.3%。结论认为吸引刮宫、球囊或手术切除在早孕期有效率达90%以上,疗效随孕周增加而下降,应尽早治疗。
要点
- 吸引刮宫成功率为202/221(91.5%;95%CI 87.8-95.2)。
- 全身甲氨蝶呤成功率最低,仅38/64(59.4%;95%CI 48.4-70.4)无需额外治疗。
- 手术治疗成功236/258(91.5%;95%CI 88.4-94.5),并发症24/258(9.3%;95%CI 6.6-11.9)。
核心结论
- 吸引刮宫、球囊治疗或手术切除在早孕期可使90%以上的剖宫产瘢痕妊娠得到有效处理。
- 所有治疗方案的疗效随孕周增加而下降,确诊后应尽早治疗。
- 局部氯化钾或甲氨蝶呤治疗效率较低且并发症率较高;全身甲氨蝶呤失败风险大、并发症率高,不应作为一线治疗推荐。
研究设计与样本
- 国际登记处研究,纳入2018年8月29日至2023年2月28日期间19个国家31个中心登记的460例剖宫产瘢痕妊娠(281例活胎、179例失败妊娠)。
- 仅纳入孕12+6周前接受积极药物或手术治疗的活胎和失败剖宫产瘢痕妊娠,期待治疗者未纳入。
- 治疗成功定义为妊娠完全消退且无需任何额外医疗干预。
主要发现
- 460例中270例(58.7%)接受手术治疗,123例(26.7%)接受药物治疗,46例(10%)接受球囊治疗,21例(4.6%)接受其他较少用治疗方案。
- 吸引刮宫成功率为202/221(91.5%;95%CI 87.8-95.2)。
- 全身甲氨蝶呤成功率最低,仅38/64(59.4%;95%CI 48.4-70.4)无需额外治疗。
- 手术治疗成功236/258(91.5%;95%CI 88.4-94.5),并发症24/258(9.3%;95%CI 6.6-11.9)。
关键数值与推荐
- 吸引刮宫成功率202/221(91.5%;95%CI 87.8-95.2)。
- 全身甲氨蝶呤成功率38/64(59.4%;95%CI 48.4-70.4)。
- 手术治疗成功率236/258(91.5%;95%CI 88.4-94.5),并发症率24/258(9.3%;95%CI 6.6-11.9)。
临床怎么用
- 作者认为剖宫产瘢痕妊娠确诊后应尽早治疗,因所有治疗方案疗效随孕周增加而下降。
- 作者认为全身甲氨蝶呤失败风险大、并发症率高,不应推荐作为一线治疗。
- 作者指出局部氯化钾或甲氨蝶呤治疗效率较低且并发症率较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A cesarean scar pregnancy is an iatrogenic consequence of a previous cesarean delivery. The gestational sac implants into a niche created by the incision of the previous cesarean delivery, and this carries a substantial risk for major maternal complications. The aim of this study was to report, analyze, and compare the effectiveness and safety of different treatments options for cesarean scar pregnancies managed in the first trimester through a registry. OBJECTIVE: This study aimed to evaluated the ultrasound findings, disease behavior, and management of first-trimester cesarean scar pregnancies. STUDY DESIGN: We created an international registry of cesarean scar pregnancy cases to study the ultrasound findings, disease behavior, and management of cesarean scar pregnancies. The Cesarean Scar Pregnancy Registry collects anonymized ultrasound and clinical data of individual patients with a cesarean scar pregnancy on a secure, digital information platform. Cases were uploaded by 31 participating centers across 19 countries. In this study, we only included live and failing cesarean scar pregnancies (with or without a positive fetal heart beat) that received active treatment (medical or surgical) before 12+6 weeks' gestation to evaluate the effectiveness and safety of the different management options. Patients managed expectantly were not included in this study and will be reported separately. Treatment was classified as successful if it led to a complete resolution of the pregnancy without the need for any additional medical interventions. RESULTS: Between August 29, 2018, and February 28, 2023, we recorded 460 patients with cesarean scar pregnancies (281 live, 179 failing cesarean scar pregnancy) who fulfilled the inclusion criteria and were registered. A total of 270 of 460 (58.7%) patients were managed surgically, 123 of 460 (26.7%) patients underwent medical management, 46 of 460 (10%) patients underwent balloon management, and 21 of 460 (4.6%) patients received other, less frequently used treatment options. Suction evacuation was very effective with a success rate of 202 of 221 (91.5%; 95% confidence interval, 87.8-95.2), whereas systemic methotrexate was least effective with only 38 of 64 (59.4%; 95% confidence interval, 48.4-70.4) patients not requiring additional treatment. Overall, surgical treatment of cesarean scar pregnancies was successful in 236 of 258 (91.5%, 95% confidence interval, 88.4-94.5) patients and complications were observed in 24 of 258 patients (9.3%; 95% confidence interval, 6.6-11.9). CONCLUSION: A cesarean scar pregnancy can be managed effectively in the first trimester of pregnancy in more than 90% of cases with either suction evacuation, balloon treatment, or surgical excision. The effectiveness of all treatment options decreases with advancing gestational age, and cesarean scar pregnancies should be treated as early as possible after confirmation of the diagnosis. Local medical treatment with potassium chloride or methotrexate is less efficient and has higher rates of complications than the other treatment options. Systemic methotrexate has a substantial risk of failing and a higher complication rate and should not be recommended as first-line treatment.
引用
- Kaelin Agten A, Jurkovic D, Timor-Tritsch I, et al. First-trimester cesarean scar pregnancy: a comparative analysis of treatment options from the international registry. Am J Obstet Gynecol. 2023. PMID: 37865390. doi:10.1016/j.ajog.2023.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。